Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero.
Keliximab is a human-cynomolgus monkey chimeric (Primatized) monoclonal antibody with specificity for human and chimpanzee CD4. As the preclinical safety assessment of biopharmaceuticals requires evaluation in pharmacologically responsive species, comprehensive toxicology studies, including reproductive toxicity, of this antibody were conducted in a human CD4 transgenic mouse model. The reproductive toxicology studies included a pre- and postnatal development study that incorporated immunotoxicological evaluation of offspring (F1) mice. The potential effects of exposure to treating maternal mice (F0) with keliximab during pregnancy and lactation on offspring viability, physical growth, neurobehavioral development, reproductive function, lymphoid tissue morphological structure, lymphocyte subsets and host resistance to Candida albicans infection were assessed. The results showed no impairment of these functions. The use of F1 transgenic mice in study with keliximab provides an example of a novel practical approach to assess developmental immunotoxicity within a study of pre- and postnatal development designed in accordance with ICH Guidelines.
Herzyk
D J
DJ
Departments of Safety Assessment, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. danuta.j.herzyk@gsk.com
Bugelski
P J
PJ
Hart
T K
TK
Wier
P J
PJ
D000367:Age Factors; D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity*; D000917:Antibody Formation / Q000187:drug effects; D015704:CD4 Antigens / Q000187:drug effects* / Q000276:immunology; D002177:Candidiasis / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D007107:Immune System / Q000187:drug effects* / Q000196:embryology / Q000254:growth & development*; D007111:Immunity, Cellular / Q000187:drug effects; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008822:Mice, Transgenic / Q000276:immunology; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D018570:Risk Assessment; D013723:Teratogens / Q000633:toxicity; D018675:Toxicity Tests / Q000379:methods / Q000592:standards; D014116:Toxicology / Q000379:methods* / Q000592:standards
D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D013723:Teratogens; C121251:keliximab